Back to companies

IPCA Laboratories Ltd: Premium Databases

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

IPCA Laboratories Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of IPCA Laboratories Insights data

Headline Published Journalists
Showing 3 of 3 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 26 Aug 2021 Lorem
Small Pharma considers RFP submissions for CROs for Phase IIb major depressive disorder trial by YE; Onyx Scientific is CMO for Phase I/IIa, exec says- CORRECTION 26 Aug 2021 William Newton
Neuronascent seeks USD 3m Series A for expanded Phase Ia Alzheimer’s trial in 2016; signs NDA for Parkinson’s asset – CEO 12 May 2016 Alissa Fleck
Neuronascent seeks USD 2m for Phase I Alzheimer’s trial - CSO 23 Apr 2014 Casey McDonald
Insights

Feature

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Benefit

Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Value

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Gain a 360-degree view of IPCA Laboratories Ltd and make more informed decisions for your business
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Start of HubSpot Embed Code End of HubSpot Embed Code